← Back to Screener
Galecto, Inc. Common Stock (GLTO)
Price$22.31
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)16.90%
Price vs S&P 500 (4W)-14.21%
VGM Score58.54
Market Capitalization$1.73B
All Metrics
Book Value / Share (Quarterly)$6.03
P/TBV (Annual)0.26x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.21
Price vs S&P 500 (YTD)-14.07%
EPS (TTM)$-12.01
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-12.01
EPS (Annual)$-18.53
ROI (Annual)-135.42%
Cash / Share (Quarterly)$5.73
ROA (Last FY)-125.14%
EBITD / Share (TTM)$-12.47
ROE (5Y Avg)-83.79%
Cash Flow / Share (Annual)$-14.14
P/B Ratio215.85x
P/B Ratio (Quarterly)0.62x
Net Income / Employee (Annual)$-4,287,800
Net Interest Coverage (TTM)-145.71x
ROA (TTM)-111.33%
EPS Incl Extra (Annual)$-18.53
Current Ratio (Annual)14.07x
Quick Ratio (Quarterly)3.71x
3-Month Avg Trading Volume0.31M
52-Week Price Return576.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.38
52-Week High$38.33
EPS Excl Extra (Annual)$-18.53
26-Week Price Return28.29%
Quick Ratio (Annual)12.65x
13-Week Price Return-24.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.73x
Enterprise Value$1.72B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$10.76
3-Month Return Std Dev82.36%
Net Income / Employee (TTM)$-3,168,800
ROE (Last FY)-135.42%
Net Interest Coverage (Annual)-151.27x
EPS Basic Excl Extra (Annual)$-18.53
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-12.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-130.67%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.41
Price vs S&P 500 (52W)549.02%
Year-to-Date Return-3.04%
5-Day Price Return-10.33%
EPS Normalized (Annual)$-18.53
ROA (5Y Avg)-74.46%
Month-to-Date Return-10.33%
Cash Flow / Share (TTM)$-1.74
EBITD / Share (Annual)$-19.22
ROI (5Y Avg)-83.79%
EPS Basic Excl Extra (TTM)$-12.01
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)0.39x
Book Value / Share (Annual)$12.02
Price vs S&P 500 (13W)-35.33%
Beta1.51x
Revenue / Share (TTM)$0.00
ROE (TTM)-130.67%
52-Week Low$2.45
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.29
4.29
4.38
4.30
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLTOGalecto, Inc. Common Stock | — | — | C | $22.31 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for cancer and liver diseases. Its pipeline includes three candidates: GB0139 for idiopathic pulmonary fibrosis, GB1211 for NASH-related fibrosis, and GB2064 for myelofibrosis.